Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics


Eton Pharmaceuticals, Inc. (ETON): $2.61

-0.01 (-0.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ETON POWR Grades


  • Value is the dimension where ETON ranks best; there it ranks ahead of 87.5% of US stocks.
  • ETON's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • ETON's current lowest rank is in the Stability metric (where it is better than 11.92% of US stocks).

ETON Stock Summary

  • ETON has a market capitalization of $104,660,517 -- more than approximately only 15.36% of US stocks.
  • Eton Pharmaceuticals Inc's stock had its IPO on November 13, 2018, making it an older stock than merely 10.73% of US equities in our set.
  • Revenue growth over the past 12 months for Eton Pharmaceuticals Inc comes in at 59,725.64%, a number that bests 99.95% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ETON, based on their financial statements, market capitalization, and price volatility, are VTVT, LPCN, PLXP, PRTA, and KROS.
  • Visit ETON's SEC page to see the company's official filings. To visit the company's web site, go to www.etonpharma.com.

ETON Valuation Summary

  • In comparison to the median Healthcare stock, ETON's price/earnings ratio is 132.05% lower, now standing at -11.7.
  • ETON's price/sales ratio has moved NA NA over the prior 34 months.
  • ETON's price/earnings ratio has moved down 4.1 over the prior 34 months.

Below are key valuation metrics over time for ETON.

Stock Date P/S P/B P/E EV/EBIT
ETON 2021-08-31 7.9 6.2 -11.7 -10.1
ETON 2021-08-30 7.8 6.1 -11.5 -9.9
ETON 2021-08-27 7.6 6.0 -11.2 -9.6
ETON 2021-08-26 7.5 5.9 -11.0 -9.4
ETON 2021-08-25 7.6 6.0 -11.2 -9.6
ETON 2021-08-24 7.4 5.8 -10.9 -9.3

ETON's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ETON has a Quality Grade of C, ranking ahead of 51.85% of graded US stocks.
  • ETON's asset turnover comes in at 0.663 -- ranking 45th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ETON's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.663 0.885 -1.378
2021-03-31 0.639 0.867 -1.807
2020-12-31 0.002 -6.333 -4.051
2020-09-30 0.028 -0.053 -3.354
2020-06-30 0.037 -0.009 -4.187
2020-03-31 0.034 0.005 -4.883

ETON Price Target

For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.5 (Moderate Buy)

ETON Stock Price Chart Interactive Chart >

Price chart for ETON

ETON Price/Volume Stats

Current price $2.61 52-week high $6.72
Prev. close $2.62 52-week low $2.47
Day low $2.58 Volume 21,000
Day high $2.68 Avg. volume 126,110
50-day MA $3.16 Dividend yield N/A
200-day MA $4.08 Market Cap 65.83M

Eton Pharmaceuticals, Inc. (ETON) Company Bio


Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.


ETON Latest News Stream


Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream


Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) have power over the company. Institutions...

Yahoo | January 10, 2022

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

Product is now available exclusively through Anovo specialty pharmacyProduct is stable at room temperature while Carbaglu® requires refrigerationEton Cares patient support program will offer $0 co-pays to commercial insurance patients DEER PARK, Ill., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutica

Yahoo | December 20, 2021

Harrow Health (NASDAQ:HROW) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, [] The post Harrow Health (NASDAQ:HROW) Downgraded by Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 19, 2021

Harrow Health (NASDAQ:HROW) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield []

Dakota Financial News | December 8, 2021

Eton Pharmaceuticals Inc. (ETON): Major Improvements, Worth A Look

Eton Pharmaceuticals Inc. (NASDAQ:ETON) concluded the trading at $3.71 on Friday, December 03 with a rise of 0.82% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.68 and 5Y monthly beta was reading 1.26 with its price kept floating in the Eton Pharmaceuticals Inc. (ETON): Major Improvements, Worth A Look Read More »

Stocks Register | December 4, 2021

Read More 'ETON' Stories Here

ETON Price Returns

1-mo -14.14%
3-mo -39.58%
6-mo -44.35%
1-year -56.57%
3-year -64.68%
5-year N/A
YTD -39.16%
2021 -47.23%
2020 12.92%
2019 17.65%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4418 seconds.